期刊
LUPUS
卷 -, 期 -, 页码 -出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/09612033231211820
关键词
Phosphatidylserine-dependent antiprothrombin antibodies; antibodies to domains of beta(2-)glycoprotein-I; anti-beta(2)Glycoprotein-I antibodies
类别
Classification criteria for antiphospholipid syndrome (APS) require specific antibodies to satisfy the laboratory disease definition, but there have been additional antibodies proposed in recent years. This article evaluates these new antibodies through the study and discussion of relevant data, and also discusses the testing of LA and the value of triple positivity.
Classification criteria for antiphospholipid syndrome (APS) require IgG or IgM isotypes of the anticardiolipin (aCL) antibodies, anti-beta 2 glycoprotein I (anti-beta 2GPI) antibodies, and/or the lupus anticoagulant (LA) to satisfy the laboratory disease definition. Over the past 20 years, non-criteria antiphospholipid antibodies (aPL) directed to other proteins of the coagulation cascade (i.e. prothrombin and/or phosphatidylserine-prothrombin complex) or to some domains of beta 2GPI have been proposed. This task force concentrated and reviewed the literature on data including aPS/PT, antibodies to domain 4/5 of beta 2GPI and the newly described antibodies to protein/HLA-DR complex. In addition, we discussed testing of LA in the 'new' oral anticoagulants' era and the value of triple positivity in the risk assessment of aPL. The conclusions were presented at a special session during the 16(th) International Congress on aPL, Manchester, UK, September 2019.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据